Having demonstrated that the Eμ-MTCP1 mouse model generates a CD19+/CD5+ B-cell malignancy with resemblance to human CLL, we proposed that this model may be ideally suited for pre-clinical evaluation of therapeutic agents for consideration in CLL and related diseases. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.